Archived Presentations

Slides available from 2020 Symposium

*Not all presenter slides were approved for release

Mir Alikhan, MD

Northshore University Health System

Caitlin Murphy, DNP, FNP-BC, AOCNP

Rush University Medical Center

Carrie Fitzpatrick, PhD

The University of Chicago Medicine

Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD

Barts Cancer Institute

Jacky Gideon, ANP

Tennessee Oncology

Pierluigi Porcu, MD

Jefferson University Hospitals

Jacky Gideon, ANP

The University of Chicago Medicine

Barbara Pro, MD

Northwestern University

Shunyou Gong, MD, PhD

Northshore University

Pankti Reid, MD

The University of Chicago Medicine

Brian Hill, MD, PhD

Northshore University Health System

Sonali Smith, MD, FASCO

University of Chicago Medicine

Nitin Jain, MD

MD Anderson Cancer Center

Neha Mehta-Shah, MD

Washington University School of Medicine in St. Louis

Erel Joffe, MD, MSc

Memorial Sloan Kettering Cancer Center

Deborah Stephens, DO

University of Utah

Brad Kahl, MD

Washington University School of Medicine

Girish Venkataraman, MD

The University of Chicago Medicine

Justin Kline, MD

The University of Chicago Medicine

Jason Westin, MD, MS, FACP

MD Anderson Cancer Center

Ari Melnick, MD

Weill Cornell Medicine

Adrian Wiestner, MD, PhD

Northshore University Health System

Krishna Komanduri, MD

Northshore University Health System

Jane Winter, MD

Northwestern University

Madhu Menon, MD, PhD

Henry Ford Health System

Slides available from 2020 Symposium

*Not all presenter slides were approved for release

18th International

Ultmann Chicago Lymphoma Symposium

CLS 2021 date
co chairs parallax bg

The International Ultmann Chicago Lymphoma Symposium (IUCLS) is an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.

We are fortunate to have a multitude of the world’s experts in lymphoma speak each year at the conference. The audience is comprised of regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that includes five academic centers.

This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. This year’s meeting will be held virtually on Friday and Saturday and will include a combination of expert presentations, a hematopathology multidisciplinary tumor board discussion, mini symposiums on Indolent lymphoma, Aggressive lymphomas, Primary and Secondary CNS lymphoma, Targeted and Cellular therapies, Imaging, and include a allied healthcare professional session. Additionally, we’ll have a special presentation regarding the impact of COVID-19 on lymphoma treatment.

Virtual symposium components will include:

  • LIVE stream session broadcast in real time
  • Opportunities to submit questions to presenters during the live broadcast
  • Ability to interact with other virtual participants via symposium attendee chat tool
  • Access to the virtual exhibit hall for connectivity and information
  • CME and MOC credits for physicians and CNE credits for nurses
  • Access to download presenter slide decks approved for release

Target Audience

The symposium has been designed for medical hematologists/oncologists, radiation oncologists, pathologists, surgical oncologists, fellows-in-training, oncology nurses, and allied health professionals committed to the diagnosis and treatment of lymphoma.

Registration Now Open

Lale Kostakoglu, MD, MPH

What is a Metabolic Tumor Volume and How may it be Leveraged in Lymphoma?

Leo Gordon, MD, FACP

Checkpoint Inhibitors in Lymphoma: Rationale Incorporation into Treatment Paradigms

Jennifer Brown, MD, PhD

Optimal Incorporation of New Targeted Agents in the Treatment of CLL

Samir Parekh, MBBS

Application of Precision Medicine in DLBCL

Jaehyuk Choi, MD, PhD

Precision Medicine in T-NHL: Where are We Now?

David Maloney, MD, PhD

Scientific Keynote: Current Applications and Future Innovation in Cell Based Therapy

Ash A. Alizadeh, MD, PhD

Circulating DNA Profiling for Lymphoma

Martin Hutchings, MD, PhD

Should PET Response Adapted Therapy be Utilized in the Therapy of NHL?

Jonathon Cohen, MD, MS

Case Based Series: Frontline Treatment Approaches for MCL

Jason Westin, MD, MS

Case Based Series: How best to Manage Patients with Relapsed MCL

Andreas Engert, MD

Clinical Keynote: Current Status and Future Directions for Newly Diagnosed Hodgkin Lymphoma

Kara Kelly, MD

Should Pediatric AYAs with Hodgkin Lymphoma be Treated Differently than Adult AYAs?

Jorge Castillo, MD

The Assessment and Treatment of Newly Diagnosed Waldenströms Macroglobulinemia

Sonali Smith, MD

How Do I Treat Limited Stage DLBCL?

Daniel J. Landsburg, MD

Novel Therapeutics for the Treatment of Relapsed/Refractory DLBCL

David Weinstock, MD

Translating Scientific Discovery in T-cell Lymphoma: Current and Future States

David Scott, MBChB, PhD, FRACP, FRCPA

Integration of Diagnostic Platforms in DLBCL

Parameswaran Venugopal, MD

DLBCL in 2016: Risk Stratification based on Clinical and Biologic Features

Lynn Wang, MD, PhD, FCAP

Ibrutinib Resistance and Implications for Clinical Practice

Elaine Jaffe, MD

The WHO classification of lymphoma: Historical Perspective and Emerging Issues

Reem Karmali, MD

No Role for Surveillance Imaging in Lymphoma (PRO)

Matt Lunning, DO

No Role for Surveillance Imaging in Lymphoma (CON)

Medhi Hamadani, MD

Beyond Matched Donors: Current Options for Allogeneic Transplantion in Lymphoma

Lindsay Morton, PhD

What Causes Lymphoma: What Should We Tell Our Patients

Youn Kim, MD

Emerging Targets, New Agents, and Improved Therapeutic Strategies in Cutaneous T-cell Lymphoma

Barbara Pro, MD

Peripheral T-Cell Lymphomas: Initial Treatment

Michele Ghielmini, MD, PhD

The Evolution Towards Non-Chemotherapeutic Approaches for Indolent Lymphomas: Pitfalls and Lessons Learned

Ann LaCasce, MD

Early Stage Hodgkin Lymphoma in 2016: Taking Stock of the Evidence

Craig Moskowitz, MD

The Status of Second-Line Thearpy in Hodgkin Lymphoma in the Near Future

Andrew Evens, DO, MSc

Management of Special Populations in Hodgkin Lymphoma

Mary Gospodarowicz, MD

Late Effects of HL Treatment: Are We Doing Any Better?

Owen O’Connor, MD, PhD

Beyond BCR Signaling: New Targets and Therapeutic Approaches in Lymphoma

Eduardo Sotomayor, MD

The Clinical Impact of Mantle Cell Lymphoma Biology

Catherine Bollard, MD

Next Steps in the Development and Application of CAR T-Cell Therapy

Justin Kline, MD

Immunology for the Lymphoma Clinician: How T-Cells and B-Cells Interact

Margaret Shipp, MD

The Translational Path of PD-1 Therapy in Lymphoma

Mitchell Smith, MD, PhD

Chemotherapy Should Be Part of Treatment for High Tumor Burden Follicular Lymphoma (PRO)

Sonali M. Smith, MD

Chemotherapy Should Be Part of Treatment for High Tumor Burden Follicular Lymphoma (CON)

Timothy Fenske, MD

Autologous SCT Should Be a Treatment Option for Relapsed Mantle Cell Lymphoma (PRO)

Patrick Stiff, MD

Autologous SCT Should Be a Treatment Option for Relapsed Mantle Cell Lymphoma (CON)

Nancy Bartlett, MD

Response Adapted Therapy in Hodgkin Lymphoma: How Should It Be Integrated for the Treatment of Patients

Richard R. Furman, MD

Molecular Prognostication of CLL in the Era of Novel Therapeutics

Michael Hallek, MD

Optimal Therapeutic Strategies for Patients with CLL in the Current Era

Jane N. Winter, MD

Prognostication of DLBCL in the Modern Era

Jeremy S. Abramson, MD. MMSc

The Definition and Most Optimal Treatment of High Risk DLBCL

James L. LaBelle, MD, PhD

Targeting Apoptosis in Lymphomas

Leo I. Gordon MD, FACP

Applications of Nanostructures in Lymphoma

George J. Weiner, MD

Implementation of CARTs in Lymphoid Malignancies

Wing C. (John) Chan, MD

Molecular Targets in T-Cell Lymphoma

David L. Porter, MD

CAR-T Cells in Lymphomas: Rationale and Current Progress

Carlo M. Croce, MD

Targeting Micro RNA’s in Lymphoma

Andrew D. Zelenetz, MD, PhD

Patients with Mantle Cell Lymphoma should Receive an Autologous Stem Cell Transplant in First Remission (CON)

Koen van Besien, MD, PhD

Patients with Mantle Cell Lymphoma should Receive an Autologous Stem Cell Transplant in First Remission (PRO)

Michael R. Bishop, MD

Patients with Relapsed DLBCL Should Receive an Autologous not an Allogeneic Stem Cell Transplant in the modern Era

John Kuruvilla, MD

Patients with Relapsed DLBCL Should Receive an Autologous not an Allogeneic Stem Cell Transplant in the modern Era

Bertrand Coiffier, MD, PhD

A Decade after R-CHOP: How should DLBCL be Treated?

Tara Henderson, MD, MPH

Survivorship of Lymphoid Malignancies for the Practitioner

Paul Rubenstein, MD

HIV-Associated Lymphomas in 2014: Spectrum of Disease and Treatment Approach

Sonali M. Smith, MD

MYC-Driven Lymphomas: Diagnostic Considerations and Management Options

Georg Lenz, MD

Dissecting Diffuse Large B-Cell Lymphoma: Why Does It Matter?

Adam Bagg, MD

The Genetics of Lymphoma

Laura Pasqualucci, MD

The Biology of B Cell Transformation

Adam M. Petrich, MD

PI3K/Akt/mTOR Inhibitors in Lymphoma: Predicting Response and Outcome

H. Miles Prince, MD, MBBS

Integrating Novel Therapies into the Management of Cutaneous T Cell Lymphomas

Oliver W. Press, MD, PhD

Emerging Immunotherapies for the Treatment of B Cell Malignancies

James Rubenstein, MD, PhD

Update on CNS Lymphomas: Primary CNS Lymphoma, Intraocular Lymphoma & Leptomeningeal Lymphoma

Bruce D. Cheson, MD

State of the Art: Staging, Restaging and Response Evaluation in Lymphomas

Sonali M. Smith, MD

Challenging Cases in Lymphoma

Andrew M. Evens. DO, MSc

Optimal Front-Line Treatment of Follicular Lymphoma

Timothy S. Fenske, MD

Timing of Hematopoietic Cell Transplantation (HCT) in Follicular Lymphoma

Brian Chiu, PhD

The epidemiology of lymphoma: lessons learned

Susan Bates, MD

Epigenetics of lymphomas: the basics and the next steps

Jonathan Friedberg, MD, MMSc

BCR signaling in lymphoma: relevance and optimal targeting

Myron Czuczman, MD

The microenvironment in lymphoma: is it druggable?

Richard Longnecker, PhD

The biology and pathogenesis of EBV-related lymphomas

Randy D. Gascoyne, MD, FRCPC

Prognostic markers in DLBCL: what is the current standard of care?

Brian Link, MD; Christopher Flowers, MD, MS

Is watch and wait still an appropriate strategy in follicular lymphoma?

Gordon, MD; Scott Smith, MD, PhD; Chadi Nabhan, MD, FACP


PTLD and Burkitt’s lymphoma

Patrick J. Stiff, MD; Koen Van Besien, MD

High risk patients with DLBCL should undergo a stem cell transplant as part of front-line treatment

Volker Diehl, MD, PhD

Hodgkin lymphoma: historical perspective and future

Richard Ambinder, MD, PhD

EBV-related Lymphomas: Prognostic and Therapeutic Implications

Ranjana Advani, MD

Current front-line approach to PTCL

Sonali Smith, MD

Autologous vs. allogeneic stem cell transplant in PTCL

Jim Armitage, MD

Treatment of Follicular Lymphoma: The Role of Transplantation in the Post-Rituximab Era

Koen Van Besien, MD

Standard Therapy for Younger Patients with Mantle-Cell Lymphoma Should Include Stem Cell Transplantation. Pro vs. Con

James Bradner, MD, MSc

Utilizing Chemical Biology to Improve Targeted Therapies in Lymphoma

Elias Campo, MD, PhD

Integrating Molecular Insights into Future Treatments for Mantle Cell Lymphoma

Bouthaina S. Dabaja, MD

Radiotherapy should be standard therapy for primary mediastinal DLBCL Pro vs. Con

Andrew Evens, DO, MS

The Biology and Treatment of Elderly Hodgkin Disease

John Gribben, MD

Importance of Immunity and the Microenvironment in Follicular Lymphoma

Paul A. Hamlin, MD

Evaluation and Treatment of Very Elderly DLBCL

John P. Leonard, MD

Standard Therapy for Younger Patients with Mantle-Cell Lymphoma Should Include Stem Cell Transplantation. Pro vs. Con

Christiane Pott, MD

Minimal Residual Disease in MCL and FL: How, Who, and When?

John M. Pagel, MD, PhD

Application of Immunoconjugates in Non-Hodgkin Lymphoma

Sonali M. Smith, MD

Case Presentation & Discussions

George J. Weiner, MD

Increasing the Efficacy of Monoclonal Antibodies

Wyndham H. Wilson, MD, PhD, NIH, NCI

Radiotherapy should be standard therapy for primary mediastinal DLBCL Pro vs. Con

Shuo Ma, MD, PhD

The Prognosis and Treatment of Elderly CLL

John Anastasi, MD

Grey-Zone Lymphomas

Stephen Ansell, MD, PhD

The Future of Monoclonal Antibodies in Lymphoma: What’s Next?

Steven Bernstein, MD

CNS Prophylaxis: Who and How?

Amy Chadburn, MD

Viral Etiology of Lymphoma

Sandeep S. Dave, MD

MiRNA in NHL

Andrew Evens, DO, MS

Northwestern University

Leo I. Gordon, MD

Purine Analogs in Indolent Lymphoma: Pro Vs. Con

Steve Horwitz, MD

How I Treat: Systemic T-NHL

Brad Kahl, MD

Management of Very High Risk DLBCL: Is There Still a Role for Front-Line Transplant

Peter McLaughlin, MD

Purine Analogs in Indolent Lymphoma: Pro Vs. Con

Ari Melnick, MD

Targeting The Germinal Center: Why and How?

Sonali M. Smith, MD

PI3K/Akt/Mtor Pathway in Lymphoma: Progress Report and Future Outlook

Scott Smith, MD

Management of Very High Risk DLBCL: Is There Still a Role for Front-Line Transplant

Philippe Solal-Celigny, MD, PhD

Keynote Lecture: Prognosis in Follicular Lymphoma in the Modern Era

Joseph Sparano, MD

HIV and NHL in 2010: State of the Art Approach To Front-Line and Relapsed Disease

Koen van Besien, MD

University of Chicago

Denis Weisenberger, MD

T-NHL: Biology and Prognostic Factors

James Cerhan, MD

Genetic Epidemiology: Implications for the Clinical Practitioner

Ken Cohen, MD

NHL microenvironment

Michael Crump, MD

Cure, Late Effects and Prevention in Hodgkin Lymphoma

Andrew Evens, DO, MS

Rational Pathways to Target in Hodgkin lymphoma

Eric Hsi, MD

Biologic predictors and implications on treatment in follicular lymphoma

Neil Kay, MD

Novel approaches and agents for the treatment of relapsed/refractory CLL

Susan O’Brien, MD

Treatment Options for Newly Diagnosed CLL

Michael Pfreundschuh, MD

Perspectives on Front-line DLBCL–Current Status and the Future

Jorge Romaguera, MD

Treatment of mantle cell lymphoma: is upfront aggressive chemotherapy and/or transplant needed?

Mathias Rummel, MD

Pro-Con: Is there a role for ASCT in follicular lymphoma?

Sonali Smith, MD

University of Chicago

Koen van Besien, MD

University of Chicago

Andreas Rosenwald

Biology and Prognosis of High Grade Lymphomas

Sonali Smith

Treatment options for relapsed DLCL

John Sweetenham

Treatment of High Grade Lymphomas

John Leonard

New Monoclonal Antibodies in NHL

John Byrd

CLL: Integration of Biology and Therapeutic Options

Andrew Evens

Challenging Cases: Elderly Hodgkin Disease and Lymphoma with Hepatitis

Julie Vose

Transformed Lymphoma: Definition, Prognosis, and Treatment

Nancy Lee Harris

Pathology and Classification of Follicular Lymphoma: WHO 2008

Thomas Witzig

Sequencing of Therapies in Follicular Lymphoma

Jane Winter

Vaccine Therapy in Lymphoma: Current State of the Art

Izidore Lossos

Gene Array and Diffuse Large B-Cell Lymphoma

Stephanie Gregory

Localized Diffuse Large B-Cell

Leo I. Gordon

Diffuse Large B-Cell Lymphoma

Lauren Abrey

Primary CNS Lymphoma—The Standard of Care

Koen Van Besien

Secondary CNS Lymphoma: Prevention and Treatment

Sonali M. Smith

Challenging Cases: Relapsed T-cell Lymphoma

Finbarr Cotter

Genetics of Mantle Cell Lymphoma: Clinical Implications

Patrick Stiff

Mantle Cell Lymphoma: Role of Stem Cell Transplantation

Martin Dreyling

Mantle Cell Lymphoma—The Next Steps

Lois Travis

Second Cancers Following Hodgkin Lymphoma

Andrew M. Evens

Hodgkin Lymphoma: Advance Stage Disease

Joachim Yahalom

Evolving Role of RT in Hodgkin’s Lymphoma

Madeleine Kraus

Pathology of Hodgkin’s Lymphoma

Volker Diehl

Treatment of Advanced Hodgkin’s Lymphoma

Joseph M. Connors

Nodular Lymphocyte Predominant Hodgkin’s Lymphoma

Andrew Evens

Challenging Cases: Hodgkin Disease with Bulky Disease and Anaplastic T-cell Lymphoma

Steven T. Rosen

Non Cutaneous T-Cell Lymphoma

Koen van Besien

Allogeneic Transplant for Low Grade Lymphoma

Sonali M. Smith

Management of Relapsed Diffuse Large B-Cell Lymphoma

Leo Gordon

Radioimmunotherapy for Low Grade and Aggressive Lymphoma

John Anastasi

Overview on Biology and Classification of Large Cell Lymphoma

Jane N. Winter



Novel Prognostic factors in Large Cell Lymphoma

Sigrid Stroobants

The Use of PET Scanning in Diagnosis and Management of Large Cell Lymphoma

Julie Vose

Monoclonal Antibodies in Aggressive Lymphomas

Wyndham Wilson

The Role of Dose Intensity in Large Cell Lymphoma

Koen van Besien

High Dose Chemotherapy in Large Cell Lymphoma

Emanuele Zucca

Biology and Treatment of Localized MALT Lymphoma

Sonali M. Smith

Management of Disseminated Marginal Zone Lymphoma